CL2008003202A1 - Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta. - Google Patents

Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.

Info

Publication number
CL2008003202A1
CL2008003202A1 CL2008003202A CL2008003202A CL2008003202A1 CL 2008003202 A1 CL2008003202 A1 CL 2008003202A1 CL 2008003202 A CL2008003202 A CL 2008003202A CL 2008003202 A CL2008003202 A CL 2008003202A CL 2008003202 A1 CL2008003202 A1 CL 2008003202A1
Authority
CL
Chile
Prior art keywords
strain
bovis
immunogenic composition
mycoplasma bovis
live attenuated
Prior art date
Application number
CL2008003202A
Other languages
English (en)
Inventor
Michael Beck
Jeffrey KNITTEL
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Publication of CL2008003202A1 publication Critical patent/CL2008003202A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA VACUNA QUE COMPRENDE CEPAS BACTERIANAS DE MYCOPLASMA BOVIS ATENUADA AVIRULENTA, DONDE DICHA CEPA SE SELECCIONA DEL GRUPO QUE CONSISTE DE: A) LA CEPA BACTERIANA DE M. BOVIS ATENUADA DEPOSITADA EN LA ATCC CON EL NÚMERO DE ACCESO PTA-8694, B) CUALQUIER CEPA BACTERIANA DE M. BOVIS DESCENDIENTE DE LA CEPA DEPOSITADA EN LA ATCC CON EL NÚMERO DE ACCESO PTA-8694, CAPAZ DE INDUCIR UNA RESPUESTA INMUNE HUMORAL EN UN TERNERO DENTRO DE LOS 14 DIAS DESPUÉS DE LA ADMINISTRACIÓN DE UNA DOSIS VÍA SUBCUTÁNEA O RUTA INTRANASAL DE UN TERNERO, Y DE NO CAUSAR SIGNOS CLÍNICOS NORMALMENTE CAUSADOS POR UNA INFECCIÓN CON UNA CEPA SILVESTRE DE M. BOVIS.
CL2008003202A 2007-10-29 2008-10-28 Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta. CL2008003202A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98348207P 2007-10-29 2007-10-29
US7555208P 2008-06-25 2008-06-25

Publications (1)

Publication Number Publication Date
CL2008003202A1 true CL2008003202A1 (es) 2009-11-27

Family

ID=40591728

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003202A CL2008003202A1 (es) 2007-10-29 2008-10-28 Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.

Country Status (14)

Country Link
US (1) US8652481B2 (es)
EP (1) EP2214702B1 (es)
JP (2) JP2011500093A (es)
KR (2) KR20160095185A (es)
CN (2) CN101827605B (es)
AR (1) AR069087A1 (es)
BR (1) BRPI0819149B1 (es)
CA (1) CA2699218C (es)
CL (1) CL2008003202A1 (es)
MX (1) MX2010003719A (es)
NZ (1) NZ585588A (es)
SG (1) SG185932A1 (es)
UY (1) UY31437A1 (es)
WO (1) WO2009058833A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030619A2 (en) * 2006-09-07 2008-03-13 Boehringer Ingelheim Vetmedica, Inc. Pcr-based genotyping
UY31437A1 (es) 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
US8503527B2 (en) 2008-10-03 2013-08-06 Qualcomm Incorporated Video coding with large macroblocks
SG10201506597RA (en) * 2008-10-31 2015-10-29 Boehringer Ingelheim Vetmed Use Of Various Antigens Including Antigens From Mycoplasma Bovis In Multivalent Vaccine Composition
UY32570A (es) * 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
KR102355614B1 (ko) * 2012-12-28 2022-01-27 베링거잉겔하임베트메디카게엠베하 마이코플라스마 항원을 포함하는 면역원성 조성물
MY173223A (en) 2012-12-28 2020-01-07 Boehringer Ingelheim Vetmedica Gmbh Method of making a mycoplasma vaccine
LT3334454T (lt) * 2015-08-14 2022-12-27 Zoetis Services Llc Mycoplasma bovis kompozicijos
CN105441368B (zh) * 2016-01-19 2019-01-01 福清市默克兽医院 一株牛支原体及其应用
CN107118262A (zh) * 2016-02-24 2017-09-01 华中农业大学 一种牛支原体MbovP579蛋白及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7007A (en) * 1850-01-08 Improvement in machinery for making cotton cordage
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
WO1999002670A1 (en) 1997-07-10 1999-01-21 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated
EP0965639A1 (en) 1998-06-05 1999-12-22 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
ATE419006T1 (de) * 1999-03-26 2009-01-15 Us Army Multivalenter dengue-virus impfstoff
BR0015398A (pt) 1999-11-08 2002-06-25 Biomune Vacinas para mycoplasma bovis e processos de uso
US6548069B2 (en) 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
MXPA03011924A (es) 2001-07-02 2004-03-26 Pfizer Prod Inc Vacuna de micoplasma hyopneumoniae y metodos para reducir la neumonia por mycoplasma bovis en el ganado.
US20030147914A1 (en) * 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
CA2457514A1 (en) 2001-08-28 2003-03-06 Pfizer Products Inc. Mycoplasma bovis challenge model, methods for administering m.bovis and methods for inducing pneumonic lung lesions
DE102004025452A1 (de) 2004-05-19 2006-01-19 Boehringer Ingelheim Vetmedica Gmbh Vakzine enthaltend BVDV
US20070009545A1 (en) 2005-07-07 2007-01-11 Joachim Frey Mycoplasma subunit vaccine
WO2008030619A2 (en) 2006-09-07 2008-03-13 Boehringer Ingelheim Vetmedica, Inc. Pcr-based genotyping
US20090068231A1 (en) 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
UY31437A1 (es) 2007-10-29 2009-05-29 Vacuna de mycoplasma bovis y métodos de uso de la misma
NZ589981A (en) 2008-07-03 2012-11-30 Univ Iowa State Res Found Inc Cattle vaccines comprising a disrupted M. bovis bacterium
SG10201506597RA (en) 2008-10-31 2015-10-29 Boehringer Ingelheim Vetmed Use Of Various Antigens Including Antigens From Mycoplasma Bovis In Multivalent Vaccine Composition
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada

Also Published As

Publication number Publication date
CN101827605B (zh) 2016-05-04
CA2699218A1 (en) 2009-05-07
US20090130148A1 (en) 2009-05-21
WO2009058833A2 (en) 2009-05-07
EP2214702A2 (en) 2010-08-11
JP5789897B2 (ja) 2015-10-07
KR20100084626A (ko) 2010-07-27
JP2013223511A (ja) 2013-10-31
EP2214702B1 (en) 2018-07-04
CN103667125A (zh) 2014-03-26
JP2011500093A (ja) 2011-01-06
CN101827605A (zh) 2010-09-08
AR069087A1 (es) 2009-12-30
AU2008318793A1 (en) 2009-05-07
UY31437A1 (es) 2009-05-29
BRPI0819149A2 (pt) 2020-08-25
EP2214702A4 (en) 2010-12-22
NZ585588A (en) 2012-09-28
SG185932A1 (en) 2012-12-28
BRPI0819149B1 (pt) 2021-11-23
CA2699218C (en) 2019-09-10
KR20160095185A (ko) 2016-08-10
KR101656301B1 (ko) 2016-09-12
WO2009058833A3 (en) 2009-06-18
US8652481B2 (en) 2014-02-18
MX2010003719A (es) 2010-04-27

Similar Documents

Publication Publication Date Title
CL2008003202A1 (es) Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.
Sarkar-Tyson et al. Progress toward development of vaccines against melioidosis: A review
CO6460761A2 (es) Vacuna viva modificada de mycoplasma bovis mejorada, métodos de producción de vacunas vivas de mycoplasma bovis, vacunas de combinación y métodos de tratamiento
AR068419A1 (es) Cepas de mycoplasma atenuadas vivas
AR068418A1 (es) Bacteria mycoplasma gallisepticum atenuada, composicion de vacuna, metodos para identificar clones de mycoplasma gallisepticum atenuados y vacunar un animal contra infeccion de mycoplasma gallisepticum
PE20011180A1 (es) Vacuna contra la salmonella materiales y metodos
hun Yoon et al. Vibrio cholerae
Kiran et al. Degradation intermediates of polyhydroxy butyrate inhibits phenotypic expression of virulence factors and biofilm formation in luminescent Vibrio sp. PUGSK8
Cha et al. Surveillance and characterization of Riemerella anatipestifer from wild birds in South Korea
DK201300292A (en) Fish vaccine
CN102154184B (zh) 减毒沙门氏菌及其应用
Mo et al. Outbreak of Edwardsiella tarda infection in farm-cultured giant mottled eel Anguilla marmorata in China
Mertins et al. Role of motAB in adherence and internalization in polarized Caco-2 cells and in cecal colonization of Campylobacter jejuni
CN104774791B (zh) 一种鸡白痢沙门氏菌sp9905及其应用
AR093424A1 (es) Vacunas atenuadas de mannheimia haemolytica y metodos para su elaboracion y uso
Lublin et al. Salmonella in Poultry and Other Birds
AR048429A1 (es) Aislados antigenicos y vacunas del virus de la bursitis infecciosa
Gowrakkal et al. Evaluation of immuno efficiency of hemorrhagic septicemia vaccine strain (vaccine seed)
Avila et al. Effects of probiotics and maternal vaccination on Salmonella enteritidis infection in broiler chicks
Bobrek et al. Erysipelas outbreaks in flocks of geese in Poland—biochemical and genetic analyses of the isolates
FI3334454T3 (fi) Mycoplasma bovis -koostumuksia
CN102716499B (zh) 一种海豚链球菌三价dna疫苗及其构建方法
Ezzat et al. Prevalence and Molecular detection of some virulence genes among Salmonella species Isolated from Poultry
CN110257274A (zh) 一种伪结核棒状杆菌致弱方法及应用
AR101538A1 (es) Cepas bacterianas que tienen actividad antimicrobiana y composiciones de biocontrol que las comprenden